Dexcom G7 Gss (161)
Payments companies reported to CMS as associated with Dexcom G7 Gss (161). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Dexcom G7 Gss (161), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Dexcom G7 Gss (161)
These are the largest totals companies reported as associated with Dexcom G7 Gss (161). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Anita Swamy | Chicago, IL | Pediatric Endocrinology | $225,041.76 |
| Pablo Mora | Dallas, TX | Endocrinology, Diabetes & Metabolism | $177,079.78 |
| Nicholas Argento | Laurel, MD | Endocrinology, Diabetes & Metabolism | $171,823.95 |
| Aaron King | San Antonio, TX | Family Medicine | $108,934.40 |
| Thomas Grace | Findlay, OH | Family Medicine | $106,208.55 |
| Catherine Kilpatrick | Fayetteville, AR | Endocrinology, Diabetes & Metabolism | $104,548.17 |
| Martin Sarkar | Frederick, MD | Endocrinology, Diabetes & Metabolism | $100,830.44 |
| Davida Kruger | Detroit, MI | Nurse Practitioner | $95,917.33 |
| Egils Bogdanovics | Torrington, CT | Endocrinology, Diabetes & Metabolism | $95,661.08 |
| Timothy Gilbert | Baton Rouge, LA | Endocrinology, Diabetes & Metabolism | $95,079.56 |
Prescribed Dexcom G7 Gss (161)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.